41 employees
Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform.
2017
$50M
from 3 investors over 3 rounds
Kelonia Therapeutics raised $50M on April 28, 2022
Investors: Venrock, Alta Partners and Horizons Ventures